| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $455...
																	Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2025 sales outlook from $11.850 billion-$12.000 billion to $11.900 billion-$12.00...
																	Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.80 per share which beat the analyst consensus estimate o...
																	
																	Wall Street opened the week on a mixed note on Monday.
																	
																	
																	
																	Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the cli...